Home » Avigen to Stop Funding AAV Program
Avigen to Stop Funding AAV Program
April 5, 2005
Biotech company Avigen said Tuesday that it will focus on developing more traditional pharmaceuticals as it discontinues funding for technology that uses viruses as a drug delivery vehicle. The company said it will stop funding its adeno-associated virus, or AAV, technology program while maintaining funding for clinical trials that are already ongoing, including a trial involving AAV for the treatment of Parkinson's disease. The company's AAV technology uses a virus to deliver therapeutic proteins to the insides of cells.
Yahoo News (http://biz.yahoo.com/ap/050405/avigen_aav.html?.v=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct